Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The LuxR-type transcriptional regulator is a bacterial protein family central to quorum sensing, the mechanism by which bacteria coordinate gene expression in response to cell density. LuxR-type proteins are generally DNA-binding transcription factors with a characteristic two-domain structure: an N-terminal domain that binds small signaling molecules known as acyl-homoserine lactones (AHLs), and a C-terminal domain that binds specific DNA motifs (lux boxes) near target promoters. Upon binding AHLs, LuxR proteins dimerize and regulate the transcription of large regulons, activating or repressing genes involved in collective behaviors such as virulence, bioluminescence, motility, secretion, and biofilm formation. LuxR acts as a global regulator, controlling hundreds of genes and integrating environmental as well as quorum-sensing signals. This regulator is essential for pathogenesis in many bacteria and is a leading anti-virulence target within infectious disease research due to its central role in bacterial communication and regulation of virulence factor production. Caveats: "LuxR-type transcriptional regulator" refers to a protein family, not a single protein, and names are organism-specific; the most studied example is LuxR from *Vibrio fischeri*, but homologs exist in many bacteria. No approved drugs yet target LuxR, but research into quorum sensing inhibitors continues.
Competitive inhibition of autoinducer (AHL) binding Disruption of LuxR dimerization or DNA binding Interference with transcriptional activation or repression of target genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LuxR-type transcriptional regulator (LuxR).